Advertisement

Subfoveal choroidal thickness as a potential predictor of treatment response after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy

Published:October 19, 2021DOI:https://doi.org/10.1016/j.jcjo.2021.09.008

      Abstract

      Objective

      To evaluate the impact of subfoveal choroidal thickness (SFCT) and other clinical biomarkers in intravitreal anti-vascular endothelial growth factor response in treatment-naive Caucasian patients diagnosed with polypoidal choroidal vasculopathy (PCV/AT1).

      Design

      Cross-sectional study.

      Participants

      Treatment-naive patients diagnosed with PCV/AT1 recruited in a single centre from January 2013 to December 2020.

      Methods

      Eligibility was determined in treatment-naive PCV patients who received a loading dose of 3 injections of 0.5 mg ranibizumab. A diagnosis of PCV/AT1 was made based on the diagnostic criteria in the efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with sumptomatic macular polypoidal choroidal vasculopathy study. Choroidal thickness was manually measured by enhanced depth imaging technology in Spectralis spectral domain optical coherence tomography.

      Results

      Eighty-three eyes of 83 patients were included in this study, 47 patients diagnosed with PCV/AT1 with a good response to 3 intravitreal injections of ranibizumab and 36 with a poor response. The receiver operating characteristic curve of treatment effect against the SFCT revealed that the area under the curve was 0.85 (range, 0.74–0.96). Based on the Youden index, the optimal SFCT cut-off point for predicting a poor response to anti-vascular endothelial growth factor is 257 µm. In the multivariate analysis, the SFCT remained statistically significant (odds ratio 1.02 [range, 1.01–1.04]; P = 0.008). The combined effect of treatment effect against clinical biomarkers produced an area under the curve of 0.90 (range, 0.82–0.98).

      Conclusion

      SFCT is a risk factor for a poor response to the 3 loading injections of ranibizumab in treatment-naive PCV/AT1 Caucasian patients. A cut-off point of 257 µm could be a valuable parameter for defining the population at risk for an inadequate response to ranibizumab.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yannuzzi LA
        • Sorenson J
        • Spaide RF
        • Lipson B.
        Idiopathic polypoidal choroidal vasculopathy (IPCV).
        Retina. 1990; 10: 1-8
        • Gomi F
        • Tano Y.
        Polypoidal choroidal vasculopathy and treatments.
        Curr Opin Ophthalmol. 2008; 19: 208-212
        • Dansingani KK
        • Gal-Or O
        • Sadda SR
        • Yannuzzi LA
        • Freund KB.
        Understanding aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy): a lesson in the taxonomy of “expanded spectra”—a review.
        Clin Exp Ophthalmol. 2018; 46: 189-200
        • Siedlecki J
        • Schworm B
        • Priglinger SG.
        The pachychoroid disease spectrum—and the need for a uniform classification system.
        Ophthalmol Retin. 2019; 3: 1013-1015
        • Lorentzen TD
        • Subhi Y
        • Sørensen TL.
        Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration: systematic review and meta-analysis.
        Retina. 2018; 38: 2363-2371
        • Kokame G
        • DeCarlo T
        • Kaneko K
        • Omizo J
        • Lian R.
        Anti–vascular endothelial growth factor resistance in exudative macular degeneration and polypoidal choroidal vasculopathy.
        Ophthalmol Retin. 2019; 3: 744-752
        • Lam WC
        • Choudhry N
        • Wong D.
        Polypoidal choroidal vasculopathy in Canada.
        Can J Ophthalmol. 2020; 55: 199-211
        • Wong C
        • Wong T
        • Cheung C.
        Polypoidal choroidal vasculopathy in Asians.
        J Clin Med. 2015; 4: 782-821
        • Cheung CMG
        • Lai TYY
        • Ruamviboonsuk P
        • et al.
        Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management.
        Ophthalmology. 2018; 125: 708-724
        • Lee WK
        • Iida T
        • Ogura Y
        • et al.
        Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study, a randomized clinical trial.
        JAMA Ophthalmol. 2018; 136: 786-793
        • Lim TH
        • Lai TYY
        • Takahashi K
        • et al.
        Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial.
        JAMA Ophthalmol. 2020; 138: 935-942
        • Cheung CMG
        • Lee WK
        • Koizumi H
        • Dansingani K
        • Lai TYY
        • Freund KB.
        Eye. 2019; 33 (Pachychoroid disease.): 14-33
        • Chang YC
        • Cheng CK.
        Difference between pachychoroid and nonpachychoroid polypoidal choroidal vasculopathy and their response to anti–vascular endothelial growth factor therapy.
        Retina. 2020; 40: 1403-1411
        • Spaide RF
        • Koizumi H
        • Pozonni MC.
        Enhanced depth imaging spectral-domain optical coherence tomography.
        Am J Ophthalmol. 2008; 146: 496-500
        • Amoaku WM
        • Chakravarthy U
        • Gale R
        • et al.
        Defining response to anti-VEGF therapies in neovascular AMD.
        Eye. 2015; 29: 721-731
      1. Early treatment diabetic retinopathy study design and baseline patient characteristics: ETDRS report number 7.
        Ophthalmology. 1991; 98: 741-756
        • Chew EY
        • Clemons T
        • Sangiovanni JP
        • et al.
        The age-related eye disease study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).
        Ophthalmology. 2012; 119: 2282-2289
        • Lee K
        • Park JH
        • Park YG
        • Park YH.
        Analysis of choroidal thickness and vascularity in patients with unilateral polypoidal choroidal vasculopathy.
        Graefes Arch Clin Exp Ophthalmol. 2020; 258: 1157-1164
        • Kong M
        • Kim SM
        • Il Ham D
        Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathy.
        PLoS One. 2017; 12: 1-13
        • Lafaut B
        • Leys A
        • Snyers B
        • Rasquin F
        • De Laey J.
        Polypoidal choroidal vasculopathy in Caucasians.
        Graefes Arch Clin Exp Ophthalmol. 2000; 238: 752-759
        • Coscas G
        • Lupidi M
        • Coscas F
        • et al.
        Toward a specific classification of polypoidal choroidal vasculopathy: idiopathic disease or subtype of age-related macular degeneration.
        Invest Ophthalmol Vis Sci. 2015; 56: 3187-3195
        • van Dijk E
        • Mohabati D
        • Veselinovic S
        • Chung W
        • Dijkman G
        • Boon C.
        The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification.
        Graefes Arch Clin Exp Ophthalmol. 2021; 259: 351-361
        • Simão J
        • Farinha C
        • Marques J
        • et al.
        Polypoidal choroidal vasculopathy in Caucasians morphological findings from multimodal retinal imaging.
        Ophthalmologica. 2021; 244: 315-325
        • Lee WK
        • Baek J
        • Dansingani KK
        • Lee JH
        • Freund KB.
        Choroidal morphology in eyes with polypoidal choroidal vasculopathy and normal or subnormal subfoveal choroidal thickness.
        Retina. 2016; 36: S73-S82
        • Kim H
        • Lee SC
        • Kwon KY
        • et al.
        Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy.
        Graefes Arch Clin Exp Ophthalmol. 2016; 254: 1497-1503
        • Ciardella AP
        • Donsoff IM
        • Huang SJ
        • Costa DL
        • Yannuzzi LA.
        Polypoidal choroidal vasculopathy.
        Surv Ophthalmol. 2004; 49: 25-37
        • Dam Lorentzen T
        • Subhi Y
        • Sørensen TL.
        Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment-naive exudative age-related macular degeneration.
        Acta Ophtalmol. 2018; 96: 475-480
        • Chen LJ
        • Cheng CK
        • Yeung L
        • et al.
        Management of polypoidal choroidal vasculopathy: experts consensus in Taiwan.
        J Formos Med Assoc. 2020; 119: 569-576
        • Cho M
        • Barbazetto IA
        • Freund KB.
        Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
        Am J Ophthalmol. 2009; 148: 70-78
        • Kokame G
        • Liu K
        • Kokame K
        • Kaneko K
        • Omizo J.
        Clinical characteristics of polypoidal choroidal vasculopathy and anti-vascular endothelial growth factor treatment response in caucasians.
        Ophthalmologica. 2020; 243: 178-186
        • Hatz K
        • Prünte C.
        Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response.
        Br J Ophthalmol. 2014; 98: 188-194
        • Kokame G
        • Lai J
        • Wee R
        • et al.
        Prospective clinical trial of intravitreal aflibercept treatment for polypoidal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
        BMC Ophthalmol. 2016; 16: 127
        • Kawamura A
        • Yuzawa M
        • Mori R
        • Haruyama M
        • Tanaka K.
        Indocyanine green angiographic and optical coherence tomographic findings support classification of polypoidal choroidal vasculopathy into two types.
        Acta Ophthalmol. 2013; 91: e474-e481
        • Tanaka K
        • Mori R
        • Kawamura A
        • Nakashizuka H
        • Wakatsuki Y
        • Yuzawa M.
        Comparison of OCT angiography and indocyanine green angiographic findings with subtypes of polypoidal choroidal vasculopathy.
        Br J Ophthalmol. 2017; 101: 51-55
        • Kang HM
        • Kwon HJ
        • Yi JH
        • Lee CS
        • Lee SC.
        Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration.
        Am J Ophthalmol. 2014; 157: 1013-1021
        • Karapetyan A
        • Ouyang P
        • Tang LS
        • Gemilyan M.
        Choroidal thickness in relation to ethnicity measured using enhanced depth imaging optical coherence tomography.
        Retina. 2016; 36: 82-90
        • Díaz-Villamarín X
        • Blánquez-Martínez D
        • Pozo-Agundo A
        • et al.
        Genetic variants affecting anti-vegf drug response in polypoidal choroidal vasculopathy patients: a systematic review and meta-analysis.
        Genes (Basel). 2020; 11: 1-13
        • Chen LJ.
        Genetic association of age-related macular degeneration and polypoidal choroidal vasculopathy.
        Asia-Pacific J Ophthalmol. 2020; 9: 104-109
        • Kuroiwa S
        • Tateiwa H
        • Hisatomi T
        • Ishibashi T
        • Yoshimura N.
        Pathological features of surgically excised polypoidal choroidal vasculopathy membranes.
        Clin Exp Ophthalmol. 2004; 32: 297-302